Cancer is a dreaded diagnosis, and the treatment doesn’t give much hope. The last statistics I looked at showed major cancer hospitals having a .25% success rate. Also, cancer is one of the fastest growing causes of mortality in the world. New research on ivermectin is showing promise as a standalone drug and as an add-on to chemo protocols.
Ivermectin is normally used as an anti-parasitic drug. You may have initially heard of it as an alternative measure in the recent pandemic. The first reports of cancer use were seen in research in 1995.
- Dr. Alfonso Duenas-Gonzales says that there are4 9 perfectly defined cancer targets.
- A Japanese study looked at lung, bone and breast cancers, and found that adding ivermectin to the protocol showed enhanced results.
- Dr. Peter P. Lee has done research with ivermectin and breast cancer.
- Dr. Martin Gleave’s research shows that ivermectin inhibits HSP27, which is a stress protein that is released after chemo and radiation therapies.
Research shows that ivermectin is beneficial for these cancers:
- Prostate
- Kidney
- Esophageal
- Breast
- Ovarian
- Lung
- Glioblastoma
- Stomach
- Colon
- Liver
- Lymphoma
- Uterus
- Pancreas and
Ivermectin inhibits cancer growth by changing its mitochondrial function, blocking its ability to grow new blood vessels, and damaging the cancer’s DNA.
Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin – PMC (nih.gov)
Ivermectin and Pembrolizumab for the Treatment of Metastatic Triple Negative Breast Cancer – NCI
Until next time,
Dr. Polly
